Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference
Cassava Sciences has announced its participation in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cassava Sciences has announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference in New York on September 13, 2022. President & CEO Remi Barbier will present in person from 3:30 PM to 4:00 PM Eastern Time. Institutional investors can request meetings through the conference's official site. A live webcast of the presentation will be available on Cassava's investors page, with an archived replay accessible for 90 days afterward. The company is focused on treating Alzheimer’s disease with its lead candidate simufilam.
Details
News Market Reaction – SAVA
The recorded move for SAVA in the trading session of this news was +0.99%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
AUSTIN, Texas, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it has been invited to present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference, being held in New York.
Remi Barbier, President & CEO, will participate in-person at this corporate event. Institutional investors who are registered for this conference may log into www.hcwevents.com to request a meeting with Cassava Sciences, pending availability.
Event details follow:
Date: Tuesday, September 13th
Time: 3:30pm to 4:00 Eastern Time
Webcast: https://journey.ct.events/view/ffcd827b-9de0-4b05-a6fd-5ea79810a3ee
A live webcast will be available on the “Investors” page of Cassava Sciences’ website, www.CassavaSciences.com. An archived replay will be available for 90 days following the event.
About Cassava Sciences, Inc.
Cassava Sciences Inc. is a clinical stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer's disease. Our novel science is based on stabilizing – but not removing – a critical protein in the brain. We are currently testing simufilam, our lead drug candidate for the proposed treatment of Alzheimer's disease dementia, in a large Phase 3 clinical program under Special Protocol Assessments from the FDA.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.